Figure 6
Effects of B 1 R blockade on brain and vascular LRP-1 and brain MMP9. (A) SSR240612 increased LRP-1 protein levels in the APP mouse brain. Vascular (arrowheads), but not neuronal (arrows), lipoprotein receptor-related protein 1 (LRP-1) immunolabeling (left) was altered by genotype and/or treatment. LRP-1 immunostaining associated to brain vessels was decreased in treated WT mice and slightly increased in untreated APP mice. SSR240612 further increased LRP-1 vascular immunoreactivity in APP mice, in the hippocampus after 5, and in both cortex and hippocampus after 10 weeks of drug administration. Scale bar: 300 μm. (B) Additionally, after 10 but not 5 weeks of drug administration, the protein levels of MMP9 were increased by 50 to 60% in the brain of treated animals. Blots images illustrate the hippocampus from the 10 weeks of treatment cohort. Error bars represent SEM. *, †P <0.05; **, ††P <0.01; ***, †††P <0.001 (†: vs. WT; *: non-treated APP vs. treated APP). Two-way ANOVA followed by Newman-Keuls post hoc test. N = 5 to 6/group. APP, amyloid precursor protein; B1R, bradykinin receptor 1; MMP9, matrix metallopeptidase 9; WT, wild-type.